Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Fiche du document
- doi: 10.1136/annrheumdis-2016-209213
- issn: 0003-4967
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/annrheumdis-2016-209213
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27821644
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-2060
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B433365195670
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Citer ce document
T. Bardin et al., « Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). », Serveur académique Lausannois, ID : 10.1136/annrheumdis-2016-209213
Métriques
Partage / Export
Résumé
Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level of ≥6.5 mg/dL (≥387 µmol/L) at screening and two or more gout flares in the prior year. Primary end point was the proportion of patients achieving sUA level of